Medium length banner heading goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

close icon
Bridging the Gap Between Lab and Market

Every Great Idea Deserves To Be A Successful Business

Ikove unlocks the potential of technology commercialization by identifying and vetting disruptive technologies at leading research labs and launching those into successful startups that deserve to be shared with humanity.

Background GraphicBackground Graphic

Our portfolio companies have been featured in these publications

Success by the Numbers

How we’ve grown

Our performance, from our founding in 2014 to the present:

Invested into our portfolio of companies
Equity value generated
Companies we have helped grow into successful businesses
AssetWatch Executive Chairman & Co-Founder, Will Zell
"Having Ikove as a founding partner in Nikola Labs was extremely helpful. I had launched two tech companies previously, and the difference between those and Nikola was substantial. Ikove brought an infrastructure of support and partnership across the critical needs every startup has, from an investor network to business development and product strategy. Nikola is where it is today as a company because of the foundation Ikove helped build."
Will Zell - Executive Chairman & Co-Founder
University Researcher
The Problem – The Valley of Death

A Significant Capital Gap Exists Between University Funded R&D and VC Funded Rounds

Universities & research institutions spend over $90 billion a year in R&D, but less than 1% is invested in commercialization efforts.

Unicorn share of venture investing has skyrocketed while early stage deals have been cut in half, ~2% of all venture deals received close to 40% of all money invested in venture.

Revolutionary IP is left sitting on the shelves at leading universities, Upwards of 95% of patented university innovations go unfunded and never reach commercial market.

Our Solution

The Startup Nursery Fund allows external, strategic investors to co-invest alongside Ikove’s Nursery.

Ikove’s Startup Nursery creates businesses around the best intellectual property funded through the research budget of leading universities.

Investors can now capitalize on exclusive opportunities related to the commercialization of disruptive intellectual property and startup companies.

investor signing papers
Ikove portfolio Company Story

DiretoTech is Scaling and Preparing for Further Growth

The DiretoTech ecosystem is focused on disrupting every step of the $75 billion per year debt collection, notification, payment, credit and cashback market in Brazil.

Direto has developed proprietary technology linking Creditors, Public Notaries and Debtors at scale, replacing an antiquated, bureaucratic, in person system, with a fully digital infrastructure.

DiretoTech consolidates five portfolio companies in order to scale nationally in Brazil and is currently raising a growth funding round.

DiretoTech Background Image
Ikove portfolio Company Story

AssetWatch, Your Partner in Eliminating Downtime

AssetWatch, formerly Nikola Labs, is the developer and provider of a rapidly deployable, end-to-end condition monitoring platform designed to prevent unplanned downtime. Unplanned downtime is a trillion dollar problem for global manufacturers. The company's wireless vibration and temperature sensors collect machine health data presented on cloud-based software and condition monitoring engineers and machine learning algorithms analyze data, providing predictive insight and enabling proactive maintenance before machines fail.

Having graduated from Ikove’s Startup Nursery, AssetWatch now proudly serves 160+ customers with systems installed in 410+ facilities.

AssetWatch Background Image
Ikove portfolio Company Story

Atreon’s Rotium Bioresorbable Wick Has Received FDA Approval

Atreon’s mission is building a line of orthopedic products that provide a structure for improved healing of sports medicine injuries.

Rotium is an electrospun, bioresorbable synthetic scaffold placed at the tendon-to-bone interface created to address the inferior healing of existing solutions. Tendon-to-Bone injuries impact over 10 million people. Rotium is designed to promote tendon healing by regenerating native tissue architecture and strong tendon-bone integration by providing a healing environment that shortens the inflammatory stage, therefore restoring function and improving procedures' success rates.

Atreon Orthopedics Background Image

Our Process

Ikove has a unique venture development model. We primarily invest in companies that we co-found. We focus on technologies coming out of Universities and Research Institutions around the country. When the circumstances are appropriate, we will also co-found joint ventures with established companies or startups. These JV’s usually develop from opportunities to establish new industry verticals or to establish operations in new geographies.

Investing in Research & Design

We Go To The Source

Ikove pursues technologies that have been developed and reinforced by significant investments in R&D at leading research institutions. Technologies are vetted through our Startup Nursery, and if they successfully move through our pipeline process, we recruit CEOs and operators to be part of the founding cap table of the companies.

Headquartered in the Midwest

We Focus Where Few Are Looking

We are headquartered in the Midwest, where we have access to world-class technologies, infrastructure and teams at a fraction of the cost of the East and West Coasts. Our CEOs can relocate the companies where they see a strategic fit but still have the benefits of lower costs and valuation arbitrage as the operating businesses settles in places like San Francisco, New York City or Hong Kong.

Business Management

We Are Founders

Ikove is heavily involved in the launch and operations of the business alongside each company’s management team. This allows the founding team to focus on the product and their market. We focus on deep tech businesses, to focus on disrupting industries that are backed by strong and significant IP.

Problem Solving

We Invest In DeepTech

We invest in technologies that solves big problems with significant market potential and are backed by strong intellectual property and knowhow.


Built to Exit

We build our companies to become fast-growing, profitable businesses that can go all the way to IPOs; but given current exit dynamics, we position our portfolio companies in a way that they can be acquisition targets. We develop our companies with a clear “build-to-sell” focus.

About Us

We pursue early-stage investments with an emphasis on technology commercialization

Through our proprietary Startup Nursery, in partnership with multiple U.S. research institutions, We identify and validate developing high-impact technologies, providing capital and commercialization resources to bridge the gap between R&D and VC funded rounds.

university technology to be commercialized
In the News

The Latest News from Ikove, Our Partners and Our Portfolio Companies

Our portfolio of companies are making noise with groundbreaking innovation.

April 4, 2023
AssetWatch, Inc., a leading condition monitoring and predictive maintenance organization, has been named a Top Workplace in the Columbus C.E.O. Magazine.
February 17, 2023
Subscribe for our News & Insights
Join our newsletter to stay up to date on features and releases.
By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Ikove makes no warranties, express or implied, regarding any of the information on this website. None of the information on this website is investment advice. This website is not a solicitation of investment or offer to purchase or sell securities.